Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bryostatin 1 in Mild to Moderate Alzheimer's Disease
NCT00606164Phase 2Unknown
- Sponsor
- West Virginia University Rockefeller Neuroscience Institute
- Start
- Apr 2008
- Primary completion
- Dec 2008
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bryostatin-1 in Alzheimer's disease (AD) (3 arms), sponsored by West Virginia University Rockefeller Neuroscience Institute. Primary endpoints: Adverse Events at 4 weeks, Alzheimer's Disease Assessment Scale at 4 weeks and 1 more. Status: unknown.
02
Drugs
bryostatin-1
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00606164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00606164.